Panel Discussion: Advancing Personalized Cancer Vaccines by Optimizing Clinical Development, Combination Strategies & Scalable Manufacturing to Achieve Commercial Reality

3:30 pm - Wednesday 2nd December 2026

  • Which patient populations and disease settings offer the greatest opportunity to demonstrate the value of personalized cancer vaccines in clinical development?
  • How should developers balance efficacy, durability, toxicity, and operational complexity when designing combination regimens?
  • What manufacturing innovations and regulatory strategies are needed to consistently deliver individualized therapies at scale?

Speakers:

Robert Dillman
Chief Medical Officer
AiVita Biomedical
Paula Pohlmann
Director, Section of Breast Cancer Clinical Research & Professor, Department of Breast Medical Oncology & Department of Investigational Cancer Therapeutics
The University of Texas MD Anderson Cancer Center
Robert Wallin
Chief Scientific Officer & Founder
SeqCure Immunology
Ira Mellman
Co-Founder & Chief Scientific Officer
Medici Therapeutics